EPA and DHA Market Report – Research, Industry Analysis Reports and Market Demands

Global EPA and DHA Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global EPA and DHA Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 EPA
- 1.3.3 DHA
1.4 Market Analysis by Source
- 1.4.1 Overview: Global EPA and DHA Consumption Value by Source: 2021 Versus 2025 Versus 2032
- 1.4.2 Fish Oil EPA and DHA
- 1.4.3 Algae Oil EPA and DHA
- 1.4.4 Others
1.5 Market Analysis by Grade
- 1.5.1 Overview: Global EPA and DHA Consumption Value by Grade: 2021 Versus 2025 Versus 2032
- 1.5.2 Food Grade
- 1.5.3 Pharma Grade
- 1.5.4 Feed Grade
1.6 Market Analysis by Application
- 1.6.1 Overview: Global EPA and DHA Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Dietary Supplements
- 1.6.3 Fortified Food and Beverages
- 1.6.4 Infant Formula
- 1.6.5 Pharmaceuticals
- 1.6.6 Pet Food
- 1.6.7 Others
1.7 Global EPA and DHA Market Size & Forecast
- 1.7.1 Global EPA and DHA Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global EPA and DHA Sales Quantity (2021-2032)
- 1.7.3 Global EPA and DHA Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: EPA and DHA by Manufacturer

3.1 Global EPA and DHA Sales Quantity by Manufacturer (2021-2026)
3.2 Global EPA and DHA Revenue by Manufacturer (2021-2026)
3.3 Global EPA and DHA Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of EPA and DHA by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 EPA and DHA Manufacturer Market Share in 2025
- 3.4.3 Top 6 EPA and DHA Manufacturer Market Share in 2025
3.5 EPA and DHA Market: Overall Company Footprint Analysis
- 3.5.1 EPA and DHA Market: Region Footprint
- 3.5.2 EPA and DHA Market: Company Product Type Footprint
- 3.5.3 EPA and DHA Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global EPA and DHA Market Size by Region
- 4.1.1 Global EPA and DHA Sales Quantity by Region (2021-2032)
- 4.1.2 Global EPA and DHA Consumption Value by Region (2021-2032)
- 4.1.3 Global EPA and DHA Average Price by Region (2021-2032)
4.2 North America EPA and DHA Consumption Value (2021-2032)
4.3 Europe EPA and DHA Consumption Value (2021-2032)
4.4 Asia-Pacific EPA and DHA Consumption Value (2021-2032)
4.5 South America EPA and DHA Consumption Value (2021-2032)
4.6 Middle East & Africa EPA and DHA Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global EPA and DHA Sales Quantity by Type (2021-2032)
5.2 Global EPA and DHA Consumption Value by Type (2021-2032)
5.3 Global EPA and DHA Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global EPA and DHA Sales Quantity by Application (2021-2032)
6.2 Global EPA and DHA Consumption Value by Application (2021-2032)
6.3 Global EPA and DHA Average Price by Application (2021-2032)

7 North America

7.1 North America EPA and DHA Sales Quantity by Type (2021-2032)
7.2 North America EPA and DHA Sales Quantity by Application (2021-2032)
7.3 North America EPA and DHA Market Size by Country
- 7.3.1 North America EPA and DHA Sales Quantity by Country (2021-2032)
- 7.3.2 North America EPA and DHA Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe EPA and DHA Sales Quantity by Type (2021-2032)
8.2 Europe EPA and DHA Sales Quantity by Application (2021-2032)
8.3 Europe EPA and DHA Market Size by Country
- 8.3.1 Europe EPA and DHA Sales Quantity by Country (2021-2032)
- 8.3.2 Europe EPA and DHA Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific EPA and DHA Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific EPA and DHA Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific EPA and DHA Market Size by Region
- 9.3.1 Asia-Pacific EPA and DHA Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific EPA and DHA Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America EPA and DHA Sales Quantity by Type (2021-2032)
10.2 South America EPA and DHA Sales Quantity by Application (2021-2032)
10.3 South America EPA and DHA Market Size by Country
- 10.3.1 South America EPA and DHA Sales Quantity by Country (2021-2032)
- 10.3.2 South America EPA and DHA Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa EPA and DHA Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa EPA and DHA Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa EPA and DHA Market Size by Country
- 11.3.1 Middle East & Africa EPA and DHA Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa EPA and DHA Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 EPA and DHA Market Drivers
12.2 EPA and DHA Market Restraints
12.3 EPA and DHA Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of EPA and DHA and Key Manufacturers
13.2 Manufacturing Costs Percentage of EPA and DHA
13.3 EPA and DHA Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 EPA and DHA Typical Distributors
14.3 EPA and DHA Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global EPA and DHA market size was valued at US$ 2479 million in 2025 and is forecast to a readjusted size of US$ 3540 million by 2032 with a CAGR of 5.5% during review period.
In 2025, global EPA and DHA production reached approximately 135,318 tons, with a average price of 17.8 USD/kg.
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are two long-chain Omega-3 polyunsaturated fatty acids that are vital for human health. They are primarily found in deep-sea cold-water fish, shellfish, and microalgae. Since the human body converts plant-derived fatty acids (ALA) into EPA and DHA with extremely low efficiency, obtaining them directly through diet or nutritional supplements remains the only practical means of maintaining adequate levels within the body.
EPA and DHA are long-chain omega-3 polyunsaturated fatty acids. EPA refers to eicosapentaenoic acid, while DHA refers to docosahexaenoic acid. They are key functional lipids associated with cardiovascular health, neurodevelopment, retinal function, inflammatory modulation, and lipid metabolism. In industrial terms, EPA and DHA are not simply equivalent to generic fish oil; they refer to nutritional ingredients, food additives, pharmaceutical raw materials, and functional health products produced from fish oil, algal oil, krill oil, and certain marine by-product oils through refining, concentration, purification, esterification, re-esterification, microencapsulation, or dosage-form processing. Commercial forms include refined oils, concentrated oils, ethyl ester oils, triglyceride oils, powders, emulsions, softgels, liquid formulations, and pharmaceutical-grade high-purity EPA/DHA ingredients. Major applications include dietary supplements, infant formula, functional food and beverages, clinical nutrition, prescription omega-3 products, and pet nutrition.
The EPA and DHA industry is mainly built around two production models: marine oil extraction and concentration, and microalgae fermentation followed by oil extraction and refining. The marine route uses sources such as Peruvian anchovy, sardine, tuna by-products, mackerel, and cod liver oil, followed by crude oil sourcing, degumming, deacidification, bleaching, deodorization, molecular distillation, esterification/re-esterification, concentration, and antioxidant stabilization to produce refined fish oil, medium-to-high concentration EPA/DHA oils, and premium rTG products. The algal route is built on microalgae strains, fermentation tanks, culture media, extraction, and refining, making it suitable for vegan, sustainable, infant nutrition, and premium supplement applications. Industry gross margins vary significantly: low-concentration refined fish oils and commodity-grade materials are typically around 12%–25%; medium-to-high concentration oils, powders, and customized formulations are around 25%–45%; pharmaceutical-grade high-purity EPA, proprietary algal oils, and high-concentration rTG products can reach around 40%–65%. Actual profitability is influenced by fish oil raw material prices, Peruvian anchovy seasons, oxidative stability, certification systems, regulatory registrations, and long-term customer contracts. The upstream chain focuses on marine resources, algal strains, and fermentation inputs; midstream competition centers on purification, concentration efficiency, odor control, contaminant management, batch consistency, and compliance documentation; downstream demand is driven by supplement brands, infant formula companies, pharmaceutical firms, functional food manufacturers, pet nutrition brands, and CDMO customers.
Market Development Opportunities & Main Driving Factors
The core market opportunity for EPA and DHA is created by the convergence of evidence-based nutrition, sustainable sourcing, and premium dosage-form innovation. Rising consumer awareness of cardiovascular management, maternal and infant nutrition, cognitive health, eye health, and proactive wellness is shifting EPA/DHA from traditional fish oil supplementation into a high-value functional lipid platform. Algal EPA/DHA is particularly attractive because it is independent of marine fisheries and fits vegan, clean-label, sustainable sourcing, and premium infant nutrition requirements. Leading companies are also moving from conventional fish oil toward proprietary algal oils, high-concentration oils, customized formulations, and pharmaceutical-grade ingredients. With the ingredient market returning to growth in 2024, high potency, low odor, smaller serving size, traceability, and compliant labeling are becoming major levers for brand differentiation.
Market Challenges, Risks, & Restraints
The main risks lie in raw material cyclicality, price transmission, quality compliance, and the boundaries of health claims. Fish oil supply is highly exposed to Peruvian anchovy seasons, El Niño events, regional quotas, and changes in fatty acid profiles, and the supply volatility after 2023 has made inventory control, long-term procurement, and multi-source sourcing more important. Although fish oil production recovered in 2024, regional declines and pricing pressure still affect margin stability. EPA/DHA is also a nutrition ingredient with strong consumer recognition and high regulatory sensitivity, requiring strict control of contaminants, oxidation indicators, heavy metals, batch traceability, label accuracy, and health claims. For smaller players, weaker raw material bargaining power, limited concentration technology, rising certification costs, and price pressure from downstream brands will continue to compress profitability in low-end products.
Downstream Demand Trends
Downstream demand is moving from single-format fish oil softgels toward multi-scenario, precise-dosage, and better-sensory formulations. Dietary supplements remain one of the largest applications, but growth is shifting toward high-concentration EPA/DHA, smaller softgels, liquid drops, gummies, emulsions, ready-to-drink products, clinical nutrition, and pet health. Infant formula and maternal nutrition emphasize stable DHA supply and high safety standards, while the pharmaceutical segment focuses on high-purity EPA or specific EPA/DHA ratios. Future competition will no longer be determined only by oil price per kilogram; it will depend on sustainability, dosage-form compatibility, odor control, oxidative stability, regulatory documentation, and co-development capability with customers. Integrated producers with algal fermentation, fish oil concentration, pharmaceutical-grade registration, microencapsulation, and finished dosage-form capabilities are positioned to gain stronger pricing power in premium nutrition and professional health markets.
This report is a detailed and comprehensive analysis for global EPA and DHA market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global EPA and DHA market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
Global EPA and DHA market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
Global EPA and DHA market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
Global EPA and DHA market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/kg), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for EPA and DHA
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global EPA and DHA market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include dsm-firmenich, KD Pharma, Croda, BASF, Yuwang Pharma, Corbion, GC Rieber VivoMega, Pelagia (EPAX), Golden Omega, TASA, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
EPA and DHA market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
EPA
DHA
Market segment by Source
Fish Oil EPA and DHA
Algae Oil EPA and DHA
Others
Market segment by Grade
Food Grade
Pharma Grade
Feed Grade
Market segment by Application
Dietary Supplements
Fortified Food and Beverages
Infant Formula
Pharmaceuticals
Pet Food
Others
Major players covered
dsm-firmenich
KD Pharma
Croda
BASF
Yuwang Pharma
Corbion
GC Rieber VivoMega
Pelagia (EPAX)
Golden Omega
TASA
KinOmega Biopharm
Omega Protein
Huatai Phrama
AlaskOmega (Wiley Companies)
Jiangsu Auqi Marine Biotechnology
Roquette
Polaris
Solutex
Sinomega Biotech Engineering
Xinzhou Marine Biological Products
ADM
Nu-Mega (Clover)
Guangdong Runke Bioengineering
Nissui
Cabio Biotech
Skuny Bioscience
Fermentalg
Renpu Pharmaceuticals
Xiamen HUISON Biotech
Xiamen Kingdomway
Algarithm
Hubei Fuxing Biological Technology
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe EPA and DHA product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of EPA and DHA, with price, sales quantity, revenue, and global market share of EPA and DHA from 2021 to 2026.
Chapter 3, the EPA and DHA competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the EPA and DHA breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and EPA and DHA market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of EPA and DHA.
Chapter 14 and 15, to describe EPA and DHA sales channel, distributors, customers, research findings and conclusion.

Buy now